CASE REPORT article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1549141
Two cases of immune-associated myocarditis caused by tislelizumab
Provisionally accepted
- 1Binzhou Medical University, Binzhou, China
- 2Department of Oncology, Affiliated Hospital of Binzhou Medical College Binzhou, binzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The current phase of immune checkpoint inhibitors has improved the clinical outcomes of many cancer therapies, however, these agents may also lead to some high consequence, immune-related adverse events. We report two cases of cancer patients treated with tislelizumab , one with liver metastases after surgery for rectal cancer and one with non-small cell lung cancer. In both cases, elevated cardiac enzyme markers were seen, and one developed fatal myocarditis, while the other was treated with high dose methylprednisolone steroid therapy and eventually improved. The probability of immune-associated myocarditis has been reported to be only 0.39 percent[1] , but once myocarditis occurs, the mortality rate is more than 50%, which is a rare but its serious side effect. Here we discuss the antitumor treatment, the mechanism of immune-associated myocarditis induced by tislelizumab , the evaluation of the association, and the treatment after the development of immune-associated myocarditis in two patients, hoping to improve the clinical awareness of immune-associated myocarditis induced by treatment with tislelizumab , and to make a timely judgment and take appropriate therapeutic measures.
Keywords: Immune related myocarditis, tislelizumab, high dose methylprednisolone steroid therapy, csae report, therapy
Received: 20 Dec 2024; Accepted: 02 Oct 2025.
Copyright: © 2025 Zhao, Wan, Wang, Zhang and Hao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yanzhang Hao, hyz022@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.